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ABSTRACT 
Objective: We have previously described that changes in the expression of Kv channels 
associate to phenotypic modulation (PM), so that Kv1.3 /Kv1.5 ratio is a landmark of 
vascular smooth muscle cells (VSMCs) phenotype. Moreover, we demonstrated that 
the Kv1.3 functional expression is relevant for PM in several types of vascular lesions. 
Here, we explore the efficacy of Kv1.3 inhibition for the prevention of remodeling in 
human vessels, and the mechanisms linking the switch in Kv1.3 /Kv1.5 ratio to PM. 
Approach and Results: Vascular remodeling was explored using organ culture and 
primary cultures of VSMCs obtained from human vessels. We studied the effects of 
Kv1.3 inhibition on serum-induced remodeling, as well as the impact of viral vector-
mediated overexpression of Kv channels or myocardin knock-down. Kv1.3 blockade 
prevented remodeling by inhibiting proliferation, migration and extracellular matrix 
(ECM) secretion. PM activated Kv1.3 via downregulation of Kv1.5. Hence, both Kv1.3 
blockers and Kv1.5 overexpression inhibited remodeling in a non-additive fashion. 
Finally, myocardin knock-down induced vessel remodeling and Kv1.5 downregulation 
and myocardin overexpression increased Kv1.5, while Kv1.5 overexpression inhibited 
PM without changing myocardin expression.  
Conclusions: We demonstrate that Kv1.5 channel gene is a myocardin-regulated, 
VSMCs contractile marker. Kv1.5 downregulation upon PM leaves Kv1.3 as the 
dominant Kv1 channel expressed in dedifferentiated cells. We demonstrated that the 
inhibition of Kv1.3 channel function with selective blockers or by preventing Kv1.5 
downregulation can represent an effective, novel strategy for the prevention of intimal 
hyperplasia and restenosis of the human vessels used for coronary angioplasty 
procedures. 
Key Words: Kv1 channels, phenotypic modulation, vascular smooth muscle, 
remodeling  
Non-standard Abbreviations and Acronyms 
PM: Phenotypic modulation 
hMA: human mammary artery 
hSV: human saphenous vein 
VSMCs: Vascular smooth muscle cells 
PAP-1: 5-(4-phenoxybutoxy) psoralen 
MgTx: Margatoxin 
SM22: Smooth Muscle 22-alpha gene, Transgelin 
αSMA: Alpha-smooth muscle actin  
MHCII: Myosin heavy chain II 
ccMYOCD: Knock-down of myocardin by using a CRISPR-Cas9 strategy 
Lv: Lentiviral vector 
AAV: Adeno-Associated viral vector 
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INTRODUCTION 
VSMCs in the vessel wall are able to switch from a contractile, quiescent state to a 
synthetic phenotype, characterized by migration, proliferation, loss of contractile 
proteins and enhanced synthesis of ECM components 1. This PM is necessary for vessel 
growth and repair, but it also contributes to the pathogenesis of atherosclerosis, vein 
graft adaptation, transplant arteriopathy, and restenosis after percutaneous 
transluminal coronary angioplasty. Vascular injury of any kind results in a stereotypical 
healing response culminating in intimal VSMC recruitment and activation, leading to 
intimal hyperplasia. PM is central to this process, which determines the progressive 
stiffening of the vessel wall and the narrowing of the vessel lumen. Despite significant 
advances in vascular biology, bioengineering, and pharmacology, restenosis remains 
the Achilles heel of percutaneous and open vascular procedures. To date, therapies 
directed to prevent restenosis include drug-eluting stents comprising a polymer-based 
delivery of either inhibitors of the mammalian target of rapamycin (mTOR) or the 
antimitotic agent paclitaxel. These are potent antiproliferative agents which also have 
additional effects on ECM synthesis. However, as they are not specific for VSMCs, an 
increased incidence of late in-stent thrombosis, due to delayed reendothelialization 
has been reported 2.  
Despite the substantial interest in the search for novel anti-restenosis therapies, the 
mechanisms of VSMC PM are incompletely understood. PM is controlled by many 
transcriptional regulatory pathways, in particular serum response factor (SRF) and its 
cofactor, myocardin 3,4. Some other repressor pathways such as Krupple-like factor-4/5 
(KLF4/5), ETS-like transcription factor-1 (Elk-1), HES-related repressor protein-1 
(Herp1), FoxO4, and the p65 subunit of NFκB, have also been suggested to act as 
molecular switches regulating VSMC differentiation (reviewed in 1,5). These 
mechanisms are not mutually exclusive, and combinations of these factors modulate 
PM through both myocardin-dependent and independent pathways.  
However, many candidates acting on some of these pathways have proven 
unsuccessful in preventing intimal hyperplasia in spite of being specific to their targets 
in in vitro studies and even effective in animal models, as was the case for the platelet 
inhibitor abciximab or the calcium channel blockers6–8 . Species and/or vascular bed 
specific processes may lie behind these discrepancies. Moreover, the use of healthy, 
large, peripheral vessels in mice to model the response of small (coronary) diseased 
vessels constitutes an important limitation. Restenosis will occur in pathological 
vessels and the underlying disease determines prognosis, evidencing the need of 
testing these novel modulators in the same vessels that can undergo vascular surgery.  
Previous work from several groups has shown that blockade of the voltage-dependent 
potassium channel Kv1.3 can represent a specific, VSMCs phenotype-dependent 
antiproliferative therapy9,10. Using an expression profile of ion channel genes in VSMCs 
from mouse femoral arteries, we showed that Kv1.3 currents were upregulated in 
proliferating VSMCs and that their selective blockade inhibited migration and 
proliferation 9. In addition, in vivo proliferative lesions in a model of endovascular 
injury were significantly reduced by systemic infusion of Kv1.3 blockers 11. Of interest, 
the increased contribution of Kv1.3 channels upon PM associates with a marked 
decreased expression of Kv1.5 channels. In fact, changes in Kv1.3/Kv1.5 ratio are a 
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conserved landmark of PM, as they have been found in all vascular beds examined, 
including human samples 12,13. In native, quiescent VSMCs, Kv1.5 is the dominant Kv1 
channel expressed, most likely forming heteromultimeric Kv1 channels 14, but in 
proliferating VSMCs, Kv1 currents are almost exclusively mediated through Kv1.3 
channels. Upon heterologous expression, Kv1.5 channels decreased proliferation while 
Kv1.3 channels increased it. Moreover, the effects on proliferation of Kv1.3/Kv1.5 
chimeras and mutant channels pinpoint key residues within the C-terminus that 
determine Kv1.3-induced proliferation 15. Based on these previous observations, we 
hypothesize that the dominant expression of Kv1.5 in Kv1 heterotetramers in 
contractile VSMC interfere with the accessibility of key docking sites at the C-terminus 
of Kv1.3 channels, thus inhibiting Kv1.3 induced-proliferation. Upon PM, the loss of 
Kv1.5 channels allows Kv1.3 voltage-induced conformational changes leading to 
activation of proliferative pathways.  
Here, we have explored the efficacy of Kv1.3 channel blockade for the prevention of 
intimal hyperplasia in human vessels and the mechanisms linking the Kv1.5 to Kv1.3 
switch to PM. Using human saphenous veins (hSV) and internal mammary arteries 
(hMA) from patients undergoing coronary bypass surgery we obtained vessel rings for 
organ culture experiments and primary VSMCs cultures. In these two preparations we 
have explored the effects of Kv1.3 blockade on the matrix synthesis or proliferative, 
and migratory responses induced by serum or PDGF stimulation. Genetic manipulation 
of Kv1.3 and Kv1.5 was used both in cell and organ culture to study the effect of these 
two channels on PM of VSMCs. Our data indicate that Kv1.5 is a contractile marker, 
whose expression levels are positively regulated by myocardin expression, so that PM 
can be prevented when overexpressing Kv1.5 channels, by a mechanism that involves 
competition with Kv1.3 channels.  
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MATERIALS AND METHODS 
The data that support the findings of this study are available from the corresponding 
author upon reasonable request. 
Samples. hMA and hSV belonging to the COLMAH collection were obtained from 
donors undergoing bypass surgery at the Clinic Hospital of Valladolid, with procedures 
approved by the Hospital Ethics Committee and according to the Helsinki Declaration. 
The vessels were collected in culture medium and used in the next 24 hours for organ 
culture, primary VSMCs culture or RNA and protein extraction. 
Organ culture and primary culture of human VSMCs. For organ culture experiments, 
hMA and hSV were cut in 5mm rings, placed in MEM culture medium (Gibco) 
supplemented with penicillin-streptomycin (100U/ml each), 5µg/ml Fungizone and 
2mM L-glutamine and kept for 2 weeks at 37ºC in 5% CO2 humidified atmosphere. 
20% Fetal Bovine Serum (FBS) was added to induce intimal hyperplasia (positive 
control), while FBS-free medium was used as negative control. Experimental conditions 
include the addition of the Kv1.3 blockers 5-(4-phenoxybutoxy) psoralen (PAP-1) or 
Margatoxin (MgTx) or other drugs as indicated to the 20%FBS medium. In all cases 
sequential sections of the same artery were used for the different experimental 
conditions. 
Primary VSMCs culture were obtained from explants of human vessels after removal of 
endothelial and adventitia layers as described elsewhere 12. Cells in passages 3-9 were 
used for proliferation, migration and electrophysiological studies. The smooth muscle 
origin of the cells was supported by their labelling with smooth muscle-specific 
antibodies such as α-smooth muscle actin (αSMA, Supplemental figure I). 
Histology and immunohistochemistry. hMA and hSV rings were embedded in paraffin 
to obtain 7µm-thick sections as described elsewhere 16. Morphometric analysis was 
performed with Masson trichrome stained sections, sequentially treated with iron 
hematoxylin (30 min), Biebrich scarlet acid fuchsin (20 min) and Light Green (3 min) 
and analyzed using computerized morphometry (ImageJ). Measures included luminal, 
intimal, media and vessel area. From these, the intima to media ratio (I/M ratio) and 
percentage of stenosis were calculated 16. For analysis of nuclei number, sections were 
incubated with Hoechst at 1:2000 for 30 minutes. Elastin abundance was quantified by 
measuring elastin auto-fluorescence.  DAB immunohistochemistry was done as 
previously described 9. Primary antibodies against Kv1.5, myocardin, SM22, MHCII and 
GFP (see the Major Resources Table in the Supplemental Material) were used at 1:50-
1:200 concentration. Secondary antibodies goat anti-Rabbit HRP (Dako) and goat anti-
Mouse HRP (DAKO) were used at 1:1000 concentration.  
RNA isolation and Real time PCR. RNA was extracted from arterial rings or cultured 
VSMCs with TRIzol Reagent following the manufacturer´s instructions, and real-time 
qPCR was performed as detailed elsewhere 12. mRNA levels were determined with 
Taqman™ assays (ThermoFisher ) in a Rotor-Gene 3000 instrument. The relative 
abundance quantification method (2-ΔCT) was used to determine mRNA levels of Kv1.3, 
Kv1.5, Calponin, Myocardin, Kvβ2, GFP and the alpha1 subunits of collagen I, III  and 
VIII, with ribosomal protein L18 (RPL18) as the housekeeping gene (see the Major 
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Resources Table in the Supplemental Material). RNA extraction from formalin-fixed 
paraffin-embedded tissue was described elsewhere 17. For the Myocardin and MRTF-A 
and MRTF-B transduced cells, ribosomal protein 18S was the housekeeping gene, null 
virus transduced cells were used as control and a Ct=40 was assigned in cases the 
expression was not detected. 
Viral vector construction and infections. Plasmids expressing the full-length Kv1.5-
EGFP, Kv1.3-Cherry, mutant WF-Kv1.3-EGFP and mutant Y2-Kv1.3-Cherry have been 
previously described 12,15.  Control plasmids coding for EGFP or Cherry inserts alone 
were used as a control. All inserts of the above plasmids were digested with the 
appropriate restriction enzymes and further subcloned into the adeno-associated viral 
(AAV) vector pAAV-MCS. Viral particles were produced using the AAV Helper-Free 
System (Agilent Technologies) according to manufacturer's instructions. Virus titration 
was done by qPCR with the primers targeting the ITRs regions: FW-ITR primer: 5´-
GGAACCCCTAGTGATGGAGTT-3´ and REV-ITR primer: 5´-CGGCCTCAGTGAGCGA-3´ 18.  
For AAV transduction of primary VSMC cultures, 60 µl of 1010 viral particles/mL (≈500 
particles/cell) were added to 80% confluent VSMC and incubated during 4h in 
Optimem medium (Invitrogen), following by 48h incubation in complete media. 
Afterwards, cells were used for proliferation, migration and electrophysiological 
studies for 3 passages at most. Efficiency of transduction was monitored by the 
expression of the reporter protein and was routinely over 80-90%.  
EGFP, Kv1.5-EGFP and Kv1.3-Cherry were also cloned into the lentiviral vector pSin-
EF2-Sox2-Pur (a gift from James Thomson, Addgene plasmid #16577), digested with 
EcoRI and SpeI. Lentiviral stocks were produced by transient cotransfection into the 
human 293FT cell line (Thermo Fisher Scientific) as described elsewhere 19. Stock Virus 
titers were between 106-108 particles/ml. VSMCs cells were transduced with a MOI of 
30-50 viral particles/cell in Optimen with 5µg/ml protamine and selected with 2 μg/ml 
puromycin for at least 5 days before assaying. 
Transduction of human coronary VSMCs (hCASMCs) was carried out using commercial 
adenoviral vectors (100 MOI: null (#1300), MYOCD (ADV-216227), MRTF-A (ADV-
215499), MRTF-B (ADV-215500); all from Vector Biolabs). hCASMCs were cultured and 
transduced as described 20,21. 
For the construction of the myocardin knock-down (ccMYOCD), we used the 
lentiCRISPR v2 plasmid, expressing a single sgRNA under the hU6 promoter and the WT 
Cas9 nuclease under the EFS promoter (a gift from Feng Zhang, Addgene plasmid 
#52961). We modified this vector replacing the unique hU6-sgRNA cloning site cassette 
with an insert containing two sgRNAs cloning sites under independent U6 promoters. 
Target sequences in myocardin exons 1 (with 5’ overhang BsmBI digestion sites) and 10 
(with 5’ overhang BsaI digestion sites) were selected with the software tool CRISPOR 22 
(see sequences in the Major Resources Table in the Supplemental Material), and the 
scores obtained are shown in Supplemental Table I. The lentiCRISPR v2 plasmid, 
expressing a single sgRNA was also used to create two other Myocardin knockdown 
vectors, targeting only exon 1 (CRISPR-1) or exon 10 (CRISPR-10), as controls for off 
target effects of ccMYOCD.  The oligos were annealed and inserted sequentially into 
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the lentiCRISPR v2 backbone. sgRNA sequences and plasmids were confirmed by 
Sanger sequencing.  
When infecting vessel in organ culture, viral incubation in Optimen lasted for 96 h in 
the presence of protamine (10µg/ml). Arterial rings were kept in culture medium with 
the indicated treatments for two weeks.  
Electrophysiological methods. Ionic currents were recorded at room temperature (20-
25ºC) using the whole-cell configuration of the patch-clamp technique. Whole-cell 
current recordings and data acquisition from cultured VSMC cells were made as 
previously described 13,23. VSMCs were perfused with a solution containing (in mM): 
141 NaCl, 4.7 KCl, 1.2 MgCl2, 1.8 CaCl2, 10 glucose, 10 HEPES, pH 7.4 (with NaOH). 0.5 
µM Paxilline was included in the bath solution to block large conductance Ca2+-
dependent K+ channels. Patch pipettes were filled with a solution containing (in mM): 
125 KCl, 4 MgCl2, 10 HEPES, 10 EGTA, 5 MgATP; pH 7.2 with KOH. Current/voltage 
curves were constructed from potentials ranging from -60 to +100mV in 10 mV steps.  
Kv1.3 and Kv1.5 components were defined as the PAP-1 (100 nM) or diphenyl-iodinium 
(DPO, 100nM) sensitive currents.  
Proliferation assays. The percentage of cells at the S phase was quantified using EdU 
(5-ethynyl-2´-deoxyuridine) incorporation for 6h with a commercial kit (Click-iT® EdU 
Imaging Cell Proliferation Assay, Invitrogen) as described 13. Briefly, 25,000 VSMCs 
were seeded onto poly-l-lysine coated coverslips placed in 12 mm wells with control 
media (10% FBS). Next day, media was replaced with serum-free (SF) media, and 
proliferation was induced by addition of PDGF (20 ng/ml), alone or in combination with 
the indicated blockers during 24 h. Determinations were carried out in triplicate 
samples and controls were included in all experiments. 
Migration assays Scratch assays were performed as described 9. Monolayers of 
confluent VSMCs were scraped with a 10 µl pipette tip and incubated in 0.5 % FBS 
medium alone or with 100nM PAP-1. Pictures were taken at 0, 4, 8, 12 and 24 hours 
from scratch and the percentage of invaded area was determined using ImageJ 
software. For Boyden chamber assay 20,000 VSMCs were seeded in polycarbonate 
inserts placed in 24 well plates (Nunc™, 140629). The well was filled with 500 µl of 
culture medium (0% or 20% FBS) and the number of migrated cells after 18h was 
determined as described 24 using ImageJ.  
Statistical analysis. Statistical Analysis was performed using Microsoft Excel and R 
studio software packages. Pooled data are expressed as means ±SEM and differences 
were considered statistically significant when p < 0.05. Shapiro-Wilk test and Bartlett’s 
test were used to test normality and homogeneity of variances respectively. For 
pairwise comparison of normal distributions, Student's t test was used, otherwise 
Mann-Whitney U test was applied. For comparisons among several groups, one-way 
ANOVA followed by Tukey’s test was employed in the case of normal distributions and 
equal variances, and Kruskal-Wallis analysis followed by Dunn’s test was applied. 
Linear correlation between variables was measured with Pearson coefficient. 
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RESULTS 
We used the ex vivo organ culture model to explore the effects of Kv1.3 blockers 
against restenosis in human vessels. First, we tested the suitability of this model, 
characterizing the preservation of tissue viability and architecture after 2 weeks 
culture, and the effect of 20% FBS treatment to promote intimal hyperplasia. Both in 
hMA and in hSV, 20% FBS incubation for two weeks led to a marked inward 
remodeling of the vessel wall, characterized by an increased thickness of intimal and 
media layers and a concomitant decrease of the lumen area (Supplemental Figure IIA, 
B). Remodeling was consistently observed in 18 out of 21 hSV and in 18 out of 20 hMA, 
Both the intima to media ratio (I/M) and the percentage of stenosis16 were significantly 
increased with FBS treatment (Supplemental Figure IIC).  Information about the sex of 
the patients was available for the majority of donors, but due to the small number of 
female samples, data were analyzed for both sexes together. In the case of hSV, we did 
not find sex differences in remodeling (Supplemental Figure IIIA, B). However, the 
small number of cases and the differences also in age distribution between sexes 
(Supplemental Figure IIIC, D) precluded any further analysis. 
Next, we determined the impact of treatment with Kv1.3 blockers on FBS-induced 
intimal hyperplasia. Incubation of hSV or hMA with the selective Kv1.3 blocker PAP-1 
(100 nM) significantly reduced 20%FBS-induced intimal hyperplasic lesions (Figure 1A, 
B). PAP-1 treatment was without effect in vessels kept in 0% FBS. FBS-induced hMA 
remodeling was also prevented with 10 nM Margatoxin (MgTx, Figure 1C) another 
selective Kv1.3 blocker not structurally related to PAP-1, suggesting that these effects 
are due to Kv1.3 inhibition.   
PM of VSMCs is the principal contributor to this vessel remodeling. Upon PM, VSMC 
dedifferentiate and show proliferative, migratory and secretory capabilities. We tried 
to identify the contribution of Kv1.3 blockade (using PAP-1) to these processes.  
Cell proliferation was analyzed both in hMA rings kept in culture (by counting the 
number of Hoechst-labelled nuclei in the intima and media layer, figure 2A) or in 
primary VSMCs cultures from these arteries, using EdU staining (Figure 2B). In both 
cases, a significant decrease of the 20% FBS (or PDGF) induced proliferation was 
observed with 100 nM PAP-1. In VSMCs cultures, the same inhibition could be 
observed upon treatment with 10 nM MgTx, and with 20 µM PD98059, a potent 
MEK/ERK inhibitor. PD98059 effect was not additive with that of PAP-1, suggesting the 
involvement of MEK/ERK in  the Kv1.3 signaling pathway, as described in other human 
VSMC cultures 13. Migration of hMA VSMCs tested with two different methods (scratch 
assay and Boyden chamber) was also inhibited by 100 nM PAP-1 treatment (Figures 2C 
and 2D). Finally, as PM also associates with an increased secretion of ECM proteins, we 
explored whether Kv1.3 blockers could modulate ECM synthesis. Collagen (particularly 
types I and III) and elastin are the most abundant proteins in the ECM of the vessel 
walls25. Upon PM, an increase in collagen synthesis and deposition (collagen I in 
particular) together with an increased secretion and disorganization of elastin fibers 
have been reported 26,27. Analysis and quantification of elastin autofluorescence shows 
an increased content upon 20% FBS incubation and a marked disorganization of the 
elastin structure (Figure 3A). Both effects are completely prevented in the presence of 
PAP-1. The same results were obtained with Orcein stain (not shown). To explore 
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changes in collagen expression, mRNA levels of the alpha subunit of collagen I and III 
(COL1A1 and COL3A1) were determined by qPCR. We also measured the mRNA 
expression levels of collagen VIII (COL8A1) a network-forming collagen type with 
increased expression in vascular remodeling in atherosclerosis models 28. COL1A1 and 
COL3A1 expression increased with 20% FBS treatment and was reduced in the 
presence of PAP-1 (Figure 3B, left), while COL8A1 expression decreased in all 
experimental conditions. However, the changes in the amount of collagen mRNA were 
determined by the dominant expression of COL1A1 and COL3A1 (right graph, Figure 
3B). Masson trichrome staining also showed an increased collagen content of arterial 
rings kept in 20% FBS, although in this case no significant effect of PAP-1 was seen 
(Figure 3C).  
These results prompted us to explore the possible mechanisms involved in the 
regulation of PM through Kv1.3 activity. Extensive studies and developmental models 
suggest that myocardin (MYOCD) has a central role in regulating smooth muscle cells 
(SMC) phenotype and SMC-specific gene expression via SRF interaction. MYOCD 
expression associates with the  contractile SMC phenotype, and its reduced 
expression/activity during PM is a key regulator of the neointima response 3,29,30. 
MYOCD induces activation of SMC promoters and SMC marker genes, including some 
ion channels like Kcnmb1 31. Therefore, we explored whether Kv1.3 and/or Kv1.5 genes 
could be also MYOCD-regulated genes.  First, we determined the expression levels of 
all Kv1 channels in human vessels, both in fresh tissue (contractile phenotype) and in 
VSMC culture (synthetic phenotype).  As previously described in other preparations 
9,23, our data confirmed the dominant expression of Kv1.5 in hMA tissue and the switch 
towards a prominent role of Kv1.3 in VSMC cultures (Figure 4A). MYOCD mRNA was 
highly expressed in hMA (t=0), and its levels significantly decreased after keeping the 
arterial rings in culture for two weeks. As expected, the decrease in MYOCD expression 
was larger when arterial rings or isolated VSMCs were cultured with 20% FBS (Figure 
4B). We explored whether MYOCD changes were associated with changes in the 
expression of Kv1.3 and Kv1.5 channels in our experimental conditions. Calponin (Cnn) 
mRNA expression levels were also determined as a positive control for a MYOCD-
regulated gene 32,33.  Figure 4D indicates a positive correlation between MYOCD mRNA 
expression and both Cnn and Kv1.5 mRNA levels. This correlation is absent when 
comparing MYOCD expression with Kv1.3, or with its accessory subunit Kvβ2. Both 
showed little variation in all conditions tested. The apparent lack of regulation of Kv1.3 
expression has been previously reported in human VSMCs cultures 13. These data 
suggest that Kv1.5 mRNA expression may be regulated by MYOCD. In fact, changes in 
Kv1.5 expression follow the same pattern of MYOCD changes (Figure 4C). To extend 
these observations we also examined correlations between Kv1.5 (KCNA5) and MYOCD 
and SRF using RNA-Seq data downloaded from the GTExPortal.org. KCNA5 correlated 
significantly with MYOCD across human tissues (examples shown in Supplemental 
Figure IV, panels A-D). Correlations were strongest in gastrointestinal organs, but 
significant also in arteries, as exemplified by the coronary artery (panel D). SRF and 
KCNA5 similarly correlated at the mRNA level (panels E through H). Taken together, 
correlation analysis at the mRNA level in our organ cultured arteries, in VSMCs  and 
using publicly accessible human expression data, support the hypothesis that Kv1.5 
may be targeted by MYOCD/SRF (as depicted at the upper right, Fig. 4). 
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Kv1.5 channels have been shown to reduce proliferation in heterologous systems12,15. 
In native VSMC, we postulated that they may inhibit proliferation by occluding Kv1.3 
channel signaling. To test this hypothesis, we designed viral vectors to overexpress 
fluorescently tagged Kv1.3 or Kv1.5 channels. The efficiency of infection was tested in 
hMA and hCA VSMCs in primary cultures. When infecting hMA VSMCs with AAV 
carrying GFP alone, Kv1.5-GFP or Kv1.3-Cherry, more than 90% of the cells showed 
reporter gene expression that could be detected in vivo (Figure 5A) or with GFP 
immunostaining (not shown). Electrophysiological studies in these cells demonstrated  
substantial expression of Kv1.5 or Kv1.3 currents (peak current density at +40 mV was 
219.76 ±36 pA/pF for Kv1.3 and 149.27±25 pA/pF for Kv1.5 infected cells, versus 8.48 
±4 pA/pF in uninfected VSMCs or 2.58 ±2 pA/pF in GFP infected VSMCs, Figure 5A,B). 
Kv1.3 currents were identified by their sensitivity to PAP-1 (as shown in figure 5A, right 
panel) and also by their more negative activation threshold (-52.27 ± 1.8 mV) 
compared to Kv1.5 infected cells (-35.28 ±2.5 mV, figure 5B, bottom panel), as 
previously described 15,34. Next, we studied VSMC proliferation in these cells. Kv1.3 
infected cells have a higher proliferation rate than GFP-infected cells, whereas Kv1.5 
overexpression significantly reduces proliferation rate, and abolished the inhibitory 
effect of PAP-1 treatment (Figure 5C). The increased proliferation rate of hMA VSMCs 
infected with Kv1.3 could not be reproduced by the Y447A mutant Kv1.3 channel 
(Kv1.3Y2, figure 5D), which has been described to abolish Kv1.3-induced proliferation 
in heterologous expression systems 15. The effects of AAV-Kv1.5 infections were also 
reproduced with Lv-Kv1.5 infections. In Lv-Kv1.5-infected cells proliferation was not 
further inhibited by PAP-1 or by Kv1.5 blockers such as DPO, consistent with the 
hypothesis that Kv1.5 inhibits proliferation by occluding Kv1.3. Moreover, 20 µM 
PD98059 inhibited proliferation to the same level in Kv1.5 and GFP expressing cells 
(Supplemental Figure V). We also explored the effect of AAV infections on hMA VSMCs 
migration using a scratch assay (Figure 5E). Whilst Kv1.5 overexpression inhibited cell 
migration, Kv1.3 or a poreless mutant (Kv1.3WF) highly increased it. 
AAV-Kv1.5 and AAV-GFP vectors were also used for infection of hMA rings in organ 
culture. The efficiency of infection was confirmed by direct visualization of GFP in 
confocal images of arterial sections, by determining GFP mRNA expression levels in the 
samples or by immunolabelling with GFP (Supplemental Figure VI) and Kv1.5 
antibodies (Figure 6A). After 14 days in culture, we found that AAV-Kv1.5 infections 
prevented 20%FBS-induced remodeling to the same extent as PAP-1 treatment. Again, 
these two effects were not additive, suggesting a common pathway (Figure 6B). Similar 
results were obtained when proliferation was measured in the arterial rings by 
counting cell nuclei (Supplemental Figure VII).  Additionally, infection of hMA rings 
with a Lv-ccMYOCD induced knock-down of myocardin (Figure 6C), together with a 
pronounced vessel remodeling in 0% FBS (Figure 6D). Due to the concerns regarding 
specificity of myocardin antibodies 35,  we also explored  expression of other 
myocardin target genes (MYHII and SM22), which were also decreased. (Supplemental 
Figure VIII). Finally, control experiments to exclude possible off-target effects of Lv-
ccMYOCD were also performed (supplemental Figure IX). In both groups of infected 
vessels, we determined the mRNA expression levels of myocardin, Cnn and Kv1.5 
mRNA (Figure 6E).  MYOCD expression decreased when arterial rings were cultured in 
the presence of 20% FBS and was unchanged by Kv1.5 overexpression in AAV-Kv1.5 
infected samples. However, MYOCD knock-down in Lv-ccMYOCD infected rings 
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decreased both calponin and Kv1.5 mRNA expression (and also Kv1.5 protein 
expression, see Figure 6C). We conclude that MYOCD expression does not depend of 
Kv1.5, but Kv1.5 behaves like a MYOCD regulated gene.  Consistent with these 
observations, overexpression of myocardin in hCASMCs using adenoviral vectors led to 
a significant upregulation of Kv1.5 mRNA, which was only partially reproduced by 
MRTF-B infection (Figure 6E). The expression levels of αSMA, a known myocardin 
target, were also determined in the same samples as a positive control (Figure 6F). 
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DISCUSSION 
In this study we identified Kv1.3 channel activity as a modulator of human VSMC 
dedifferentiation, migration and proliferation. Our results uncovered several major 
findings. First, using human vessels (mammary arteries and saphenous veins) in organ 
culture, we demonstrated that inhibition of Kv1.3 channels can prevent unwanted 
remodeling.  Second, we provided evidence suggesting that MYOCD-dependent 
expression of Kv1.5 channels, via modulation of the Kv1.3/Kv1.5 ratio in VSMCs, 
underlies the changes in the functional contribution of Kv1.3 channels to PM. Third, by 
using viral vectors to overexpress Kv1.5 and Kv1.3 (WT or mutant) channels we 
demonstrated that Kv1.5 channels inhibit vascular remodeling by occluding Kv1.3 
activity. We propose that upon PM reduction of Kv1.5 uncovers Kv1.3-dependent 
signaling pathways leading to proliferation and migration.  Altogether, these data 
indicated that blockade of Kv1.3, either with selective inhibitors or with Kv1.5 
overexpression could represent an effective novel strategy for the prevention of 
intimal hyperplasia in human vessels in vivo. 
Kv1.3 channel have been shown to be involved in cell proliferation in many cell types, 
including immune system cells, glial cells, VSMCs  and cancer cells 36. With the 
exception of T-lymphocytes, all these cells express other Kv1 channels, whose levels 
are also altered upon activation. Specifically, downregulation of Kv1.5 channels often 
associates  with Kv1.3 upregulation in proliferating cells 13,37,38. On these grounds, we 
proposed that the relative amount of these two channels (the Kv1.3/Kv1.5 ratio) could 
represent the master switch determining the Kv1 channel effect on proliferation. In 
several human and mouse vessels we have previously found a dramatic decrease of 
Kv1.5 expression upon PM or in response to mitogens, with no significant changes in 
Kv1.3 expression 12,13. Here, we confirmed this notion in organ culture experiments of 
human vessels. There is a clear relationship between Kv1.5 mRNA levels and PM; in 
fact, we show for the first time that Kv1.5 expression is regulated by myocardin. 
Myocardin knock-down decreased expression of Kv1.5 and myocardin overexpression 
increases it, while Kv1.5 overexpression inhibits PM without affecting myocardin 
expression (Figure 6). Altogether, these data indicated that not only there is a 
correlation between myocardin and Kv1.5 expression levels but also that Kv1.5 
expression is regulated by myocardin, confirming our hypothesis that Kv1.5 is another 
SM-specific differentiation marker, in the same way as other contractile proteins. 
Indeed, when we leveraged publicly accessible human RNA-Seq data (GTExPortal.org) 
for correlation analysis, highly significant correlations were found in several tissues 
including the coronary artery. In addition, Kv1.5 expression shows a very high 
expression in heart and arteries (https://gtexportal.org/home/gene/KCNA5), and 
seems to be mainly located  in cardiac and smooth muscle.  
These data suggest that Kv1.5 downregulation is the relevant change for PM and VSMC 
proliferation. We propose that two mechanisms can underlie Kv1.5-mediated 
inhibition of PM: activation of antiproliferative signaling pathways and/or prevention 
of Kv1.3-induced proliferation.  Heterologous expression of Kv1.5 in HEK cells inhibits 
proliferation, supporting the first option 12,15. However, this may not be the case in 
native systems, where Kv1.3 and Kv1.5 are likely to form heteromultimeric channels, 
as has been described for several Kv1 channels 39–41. Here we demonstrate that Kv1.5 
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overexpression inhibits PM both in organ culture and in cultured VSMCs (Figures 5-6). 
In both preparations, the effects of Kv1.5 overexpression can be reproduced with 
Kv1.3 blockade, and the two effects are non-additive. The interference of Kv1.5 with 
the pro-proliferative signaling pathways activated by Kv1.3 protein is the simplest 
explanation for these data.  
In addition, adenoviral expression of mutant Kv1.3 channels provided some other 
relevant conclusions regarding the mechanisms involved in Kv1.3 induced proliferation 
of VSMCs. Initially, we could think of two non-exclusive mechanisms: either VSMCs use 
Kv1.3 channels to regulate resting membrane potential (and hence cell cycle), or Kv1.3 
channels may serve as sensors of changes in membrane potential, acting as a signaling 
molecule connecting bioelectrical signals with intracellular pathways. In heterologous 
systems, K+ fluxes through Kv1.3 channel are not required for proliferation, but the 
response needs a voltage-dependent conformational change of the channel 12.  The 
effect of overexpressing the Kv1.3 poreless channel (Kv1.3WF, Figure 5E) indicates 
that, also in VSMCs, K+ fluxes are not required for Kv1.3-induced proliferation. 
Moreover, it has been reported that at least two single phosphorylation sites in the C-
terminal region of the channel could recapitulate Kv1.3-induced proliferation, as their 
individual mutation abolished the effect 15. Here, we found that overexpression of 
Kv1.3 (but not of the phosphorylation-deficient channel Kv1.3Y2), increased VSMCs 
proliferation, indicating the requirement for interaction of Kv1.3 protein with other 
partners (via phosphorylation of the channel) to activate proliferation. Altogether, our 
data suggest that there is a specific requirement for Kv1.3 channel protein to facilitate 
proliferation, regardless of Kv1.3 channel ion flux. The nature of these interacting 
proteins and the detailed molecular mechanisms activating Kv1.3-induced proliferation 
await future research.  
In addition to providing relevant information regarding the mechanisms contributing 
to PM, our work has another relevant added value: exploring these mechanisms in the 
remodeling of human vessels. The reduction of in-stent restenosis of both rapamycin- 
and paclitaxel-eluting stents has translated into their widespread use. However, their 
lack of specificity with the subsequent failure of healing 42 calls for the development of 
newer agents and/or polymers for stent coverings. In this scenario, we propose a novel 
strategy (Kv1.3 channel blockade) whose efficacy has been previously tested in animal 
lesion models. However, it is well known that these models have many limitations: 
they are not restenosis models, neointima formation is not always associated with 
lumen narrowing, rodent vessels do not behave like human vessels and healthy vessels 
do not behave like diseased vessels, because of  differences in cell cycle regulation 
between dedifferentiated VSMCs in the lesion and normal VSMCs 43,44. Using the same 
human vessels that are commonly used for coronary angioplasty, we demonstrate 
here that local Kv1.3 channel blockade (by application of selective inhibitors or by 
Kv1.5 overexpression) is an efficient strategy to prevent vascular remodeling. These 
interventions inhibit neointima formation by reducing VSMC proliferation and 
migration and ECM production. It is likely that they could also reduce remodeling by 
acting on other targets aside from VSMCs. Kv1.3 blockers modulate  the immune 
responses 45, have anti-inflammatory effects by inhibiting migration, proliferation and 
NOS expression in macrophages 46, and can exert anti-thrombotic effects 47. Thus, by 
targeting several biological processes involved in restenosis (inhibiting PM of VSMCs, 
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decreasing fibrosis, inflammation and platelet aggregation), Kv1.3 inhibitors could 
represent very good candidates for the prevention of unwanted remodeling in human 
vessels.  
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HIGHLIGHTS  
1. Kv1.3 channel blockade prevented remodeling of human vessels in organ 
culture by inhibiting VSMC proliferation and migration and ECM secretion. 
2. Kv1.3 channel behaves as a housekeeping gene, while Kv1.5 channel is a 
myocardin-regulated, VSMC contractile marker. The increased functional 
contribution of Kv1.3 channels in dedifferentiated VSMCs is a consequence of 
the myocardin-dependent downregulation of Kv1.5 channels. 
3. Kv1.5 overexpression inhibited human vessels remodeling by hampering Kv1.3-
induced migration and proliferation. 
4. Inhibition of Kv1.3 channel function with selective blockers or by preventing 
Kv1.5 downregulation can represent an effective strategy for the prevention of 
intimal hyperplasia in human vessels. 
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FIGURE LEGENDS 
 
Figure 1. Kv1.3 blockers inhibited FBS-induced vascular remodeling.  
A. Representative microphotographs of hSV kept in organ culture for two weeks in serum free 
conditions (0FBS), or in the presence of 20% Fetal bovine serum (20FBS) alone or combined 
with PAP-1 (100 nM). Images were taken with a 10X objective (NA=0.3). L = lumen side. The 
black arrows indicated the thickness of the intima layer, and the arrowheads the 
media/adventitia border. The average data (mean ±SEM) of the intima/media ratio obtained in 
12 different vessels is represented in the right plot. B. A similar experiment carried out in hMA 
in the same experimental conditions. hMA do not present intima layer in the absence of FBS. 
The bars plot shows average data of 8-15 arteries. Notice the lack of remodeling and the 
absence of effect of PAP-1 treatment in 0FBS conditions, compared to control vessels not 
maintained in organ culture (t=0). C. Representative microphotographs of the inhibitory effect 
of MgTx (10nM) on 20% FBS-induced remodeling of hMA. Summary data were obtained from 4 
arteries. * p<0.05; **p<0.01; ***p<0.001 with respect to 20%FBS, for paired data. Scale 
bar=100 µm.  
Figure 2. Kv1.3 blockers inhibited proliferation and migration.  
A. Number of nuclei present in the intima and media layer of hMA rings kept in control 
conditions (0% FBS), with 20% FBS alone or in the presence of 100 nM PAP-1. hMA sections 
were stained with Hoechst, and the nuclei present in the intima and media layer in four, 225 
µm wide sections for each sample were counted. Representative images (10X objective) are 
depicted as an inset (Scale bar = 100 µm). L = lumen side. Bars plot shows the mean ± SEM of 
4-10 arteries in the indicated conditions. ** p<0.01; ***p<0.001 with respect to 20% FBS. B. 
Proliferation of hMA VSMC in primary culture was determined by EdU incorporation, after a 
24h treatment in serum free conditions (0FBS) or in the presence of 20ng/ml PDGF alone or in 
combination with the indicated drugs (PAP-1 100nM; Margatoxin 10 nM; PD98059 20µM). 
Each data bar is the mean ± SEM of 12-40 individual determinations obtained in at least 5 
independent experiments. Positive and negative controls were included in all experiments. 
***p<0.001 with respect to PDGF alone. C. Representative examples of a scratch migration 
assay in control conditions (left) or in the presence of PAP-1 (right) and bars plot with the 
summary data of the percentage of invaded area at 4h. Each bar is the average ± SEM of 18 
individual experiments from 7 different primary VSMCs cultures. ***p<0.001. D. Data of 
Boyden chamber migration assay representing the cell number that migrated to the lower side 
of the chamber after 18h of treatment. Mean ±SEM, n=9.  ***p<0.001 with respect to 20%FBS.  
Figure 3. Kv1.3 blockade inhibited ECM secretion in organ culture. 
A. Microphotographs of rings of the same hMA incubated in the indicated conditions, showing 
elastic lamina auto-fluorescence in green and Hoechst stained nuclei in blue. Images were 
taken with a 20X objective (NA=0.5). Scale bar = 100µm. The elastin area labelled was 
quantified (see methods) and average data of 9 experiments (Mean ± SEM) is shown in the 
plot. *p<0.05, **p<0.01 compared with 20% FBS, paired data. B. mRNA expression of COL1A1, 
COL3A1 and COL8A1 genes was determined in hMA rings in control conditions (t=0) or after 2 
weeks in organ culture in the indicated conditions.  RPL18 was used as housekeeping gene to 
obtain mRNA amount (2-∆Ct, right). Also, data were normalized to the t=0 condition with the 2-
∆∆Ct relative quantification method, where ∆∆Ct = ∆Ctexperimental-∆Ctcalibrator (left). Data are mean± 
SEM obtained from triplicates of at least 5 different samples. *p<0.05 compared to 20% FBS. C. 
An estimation of the collagen content was obtained by quantifying the green-stained area of 
intima and media layers using the Masson trichrome. Representative microphotographs (scale 
bar = 100 µm, 10X objective) and pooled data (Mean ± SEM, n=9). *p<0.05 compared to 
20%FBS.  L = lumen side. 
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Figure 4. Kv1.5 (but not Kv1.3) mRNA expression correlates with Myocardin.  
A. Relative mRNA abundance of the voltage-dependent potassium channel Kv1 family genes in 
contractile (tissue) and proliferating (culture) VSMC from human mammary arteries. 
Expression levels were normalized with respect to RPL18 and expressed as 2–∆Ct, where 
∆Ct=Ctchannel-CtL18s. Each bar is the mean of 4 to 6 determinations from different donors 
obtained in triplicate assays. The relative abundance (in %) of each Kv1 subfamily member in 
both conditions is indicated in the bars plot and also illustrated in the pie-charts.  B, C. Real 
time qPCR with Taqman probes were used to determine mRNA expression of Myocardin (B) 
and KCNA5 (the Kv1.5 gene, C). In both cases, mRNA abundance is expressed as 2-∆Ct, relative 
to RPL18. mRNA was obtained from fresh untreated arterial rings (t=0), arterial rings kept 2 
weeks in organ culture in the indicated conditions and from cultured hMA VSMCs. In both 
graphs, * p<0.05, **p<0.01, ***p<0.001 with respect to untreated tissue (t=0) and $= p<0.05 
compared with 0% FBS samples (n=8-10 determinations). D. The graphs show the correlation 
in each sample (n=30 for each data set) between the relative abundance of MYOCD and the 
relative abundance of KCNA5 (Kv1.5, black triangles) and CNN1 (Calponin, grey circles, upper 
plot) or KCNA3 (Kv1.3, open circles) and KCNAB2 (Kvβ2, black squares, lower graph). The lines 
show the fit of the data to a linear function. Pearson correlation coefficients were 0.83 
(Calponin), 0.765 (Kv1.5), 0.15 (Kv1.3) and -0.19 (KCNAB2).  
Figure 5. Characterization of AAV-mediated overexpression of Kv1.3 and Kv1.5 in 
hMA VSMCs. 
A. Representative current-voltage (I/V) curves obtained in hMA VSMCs infected with AAV-GFP, 
AAV-Kv1.5 (Kv1.5-GFP) and AAV-Kv1.3 (Kv1.3-Cherry). Currents were elicited by pulses from -
60 to +60 mV in 10 mV steps. The current traces elicited are shown in each case. For Kv1.3, the 
I/V curve obtained in the presence of 100 nM PAP is also shown. The microphotographs show 
efficiency of the infections by direct visualization of the fluorescent tags. B. (top) Bar plot 
showing peak current density (pA/pF) at +40mV obtained in control cells and in cells infected 
with the three types of AAV. N= 8-11 cells in each group from at least 3 independent 
experiments. The bar plot at the bottom shows the activation threshold estimated in the same 
conditions. Only Kv1.3-overexpressing VSMCs showed a shift towards a more negative 
threshold. Data are Mean ± SEM of 6-9 cells in each group. C. Effect of AAV-mediated 
overexpression on cell proliferation. Proliferation rate was calculated as the percentage of cells 
incorporating EdU. hMA VSMCs infected with AAV-GFP, AAV-Kv1.3 or AAV-Kv1.5 were 
incubated for 30 h with PDGF (20 ng/ml) alone or in combination with 100 nM PAP-1. EdU 
reagent was added to the media during the last 6 h of incubation. Each bar is mean ± SEM of 
12-25 individual determinations from at least 4 independent experiments. **p<0.01, 
***p<0.001 compared to control (GFP); $ p<0.05, $$$p<0.001 compared to their own control 
(PAP-untreated VSMCs). D. Proliferation rate obtained in another set of experiments exploring 
the effect of overexpression of Kv1.3 phosphorylation-defective mutant (Y2). N = 12-22 
independent experiments from 5-10 different cultures. E. Scratch assay was used to determine 
the time course of migration of AAV-infected hMA VSMCs overexpressing GFP, Kv1.5, Kv1.3 or 
a poreless Kv1.3 mutant (WF). Mean ± SEM, n=4. *p<0.05, **p<0.01 compared to control, GFP-
infected VSMCs; $ p<0.05 compared to Kv1.3. 
Figure 6. Overexpression of Kv1.5 channel reduces intimal hyperplasia in hMA.  
A. Immunohistochemical labelling ofKv1.5 in paraffin-embedded cross-sections from hMA 
infected with AAV-GFP or AAV-Kv1.5 and kept in organ culture with 20% FBS. 20X objective, 
scale bar = 100µm. B. Effect of Kv1.5 overexpression on intimal hyperplasia induced by 20% 
FBS. Intima to media ratio was calculated in control samples (GFP-0%FBS) or in GFP or Kv1.5-
infected samples incubated with 20% FBS alone or in combination with PAP-1 (100nM) as 
indicated. Each bar is the mean ± SEM of 3-6 experiments. *p<0.05, **p<0.01, ***p<0.001 
compared to 0% FBS-GFP. Representative microphotographs of hMA sections stained with 
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Masson trichrome in the three indicated conditions are shown in the left. Scale bar = 100µm. 
C. Immunohistochemical labelling for Myocardin (upper panels) and Kv1.5 (lower panels) of 
paraffin-embedded cross-sections of hMA infected with Lv-GFP (left and right panels) or the 
myocardin knock-down Lv-ccMYOCD (middle panels). Arterial rings were kept in organ culture 
for 14 days in 0% FBS or 20% FBS (right upper panel). Right bottom panel show the negative 
control for the Kv1.5 labelling in a GFP-0% FBS sample. 10X objective, scale bar 100µm. D. 
Effect of Myocardin knock-down on PM. Bar plot represents average data (mean ±SEM) of the 
intima/media ratio obtained in Lv-GFP-infected vessels kept in 0% FBS or 20% FBS  or Lv-
ccMYOCD-infected vessels kept in 0%FBS (middle bar); n=3. Representative microphotographs 
of the GFP and ccMYOCD-infected vessels in are depicted in the right. Arrows indicate 
neointima, scale bar 100µm. E. The left panel shows qPCR determination of the relative 
amount of Myocardin or endogenous Kv1.5 mRNA in hMA infected with AAV-GFP (kept in 0% 
or 20%FBS) or AAV-Kv1.5 (in 20%FBS) as in B. The right plot shows mRNA expression of 
myocardin, Kv1.5 or calponin in hMA infected with Lv-GFP (in 0% and 20%FBS) or Lv-ccMYOCD 
(in 0%FBS) as in D. Data are Mean ± SEM of 3- 5 independent experiments. ** p<0.01; 
***p<0.001 with respect to 0%FBS-GFP. F, G. mRNA expression of Kv1.5 (F) and smooth 
muscle actin (αSMA, G), were determined in hCASMCs transduced with a null adenovirus 
vector (control) or with adenovirus overexpressing MYOCD, MRTF-A and MRTF-B  as indicated. 
18s was used as housekeeping gene to obtain mRNA amount and data were normalized to the 
control condition with the 2-∆∆Ct relative quantification method, where ∆∆Ct = ∆Ctexperimental-
∆Ctcontrol. Data are mean± SEM obtained from duplicates of 5 different infections. *p<0.05; ** 
p<0.01; ***p<0.001 with respect to control.  
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Supplemental Figures and Figure Legends 
 
 
Supplemental Figure I. Alpha Smooth Muscle Actin (αSMA) labelling in primary VSMC 
culture.  Representative microphotographs showing  immunocytochemical labelling 
with αSMA  antibody of  primary VSMCs cultures at passage 7-8 obtained from human 
saphenous veins (hSV, A) and human mammary artery (hMA, B and C).  While αSMA  
labelling was detected in most cells  in hSV VSMCs even when they are kept in 10% 
FBS,  in hMA expression of αSMA showed a weaker signal in these conditions (B) that 
could be increased upon treatment of the cells with serum free medium for  96h (C), a 
condition known to upregulate the expression of contractile proteins. 
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Supplemental Figure II. FBS induces vascular remodeling after 2 weeks in organ 
culture. A and B. Representative microphotographs of hMA (A) and hSV (B) stained 
with Masson trichrome after two weeks  kept in organ cultured without (0%FBS) or 
with 20% FBS. The upper panels show images of the vessel rings (objective 4X, 
NA=0.13), and a section of the ring (indicated by the dotted square) is amplified in the 
lower panels, showing the presence of neointima (in hMA) or its increase (in hSV ) 
upon 20% FBS treatment. Scale bars= 500 µm (upper panels) and 100 µm (lower ones). 
L = lumen side. C. Vascular remodeling was quantified by determining the 
Intima/media ratio and % stenosis after two weeks in 0% FBS (white bars) or 20% FBS 
(gray bars). I/M ratio represents Intima area/Media area. Percentage of stenosis was 
calculated as : %stenosis = 100·(Intima area–Lumen area)/Intima area. Each bar is the 
Mean ± SEM of 18 hMA or 16 hSV. ***p<0.001 for paired data.  
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Supplemental Figure III. Organ culture of hSV does not have sex difference in the 
FBS- induced vascular remodeling.  A and B. Comparison of vascular remodeling in 
male and female hSV. The bar graphs show no differences in intima/media ratio (A) 
and % stenosis (B) between male and female samples. Data presented as Mean ± SEM, 
male n=12, female =4. ** p<0.01, ***p<0.001 as compared to 0%. C. Sex and age 
distribution (and percentages) of the mammary arteries and saphenous vein samples 
used in our study from which we could collect this information.  D. Box plot showing 
the age distribution of the male and female hSV samples.  
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Supplemental Figure IV. KCNA5 correlates with MYOCD and SRF at the mRNA level 
across human tissues. RNA-Seq data was downloaded from the GTExPortal.org and 
normalized as described (Krawczyk KK, et al., 2015). Correlations were tested in 
stomach (N=262), ileum (N=137), tibial nerve (N=414) and coronary artery (N=173) 
using Log2 transformed expression data and the Spearman method in GraphPad Prism. 
P-values, and Spearman Rho values are given in the panels (A through H). Straight 
white lines represent best linear fits. 
  
6 
 
 
Supplemental Figure V. Effect of Kv1.5 overexpression in VSMC proliferation. Bar plot 
showing the proliferation rate of human coronary VSMCs infected with lentiviral 
vectors overexpressing GFP (white bars) or Kv1.5 (grey bars). Cells were incubated in 
control media alone or with 100 nM PAP-1 (PAP), 20µM PD98059 (PD98) or 2µM 
Diphenyl phosphine oxide-1 (DPO). All these treatments produced a significant 
decrease of proliferation in Lv-GFP cells, but only PD treatment inhibited Lv-Kv1.5 cells. 
Data presented as mean ± SEM, n=6-15 data from 3-6 different experiments. 
***p<0.001 as compared to Lv-GFP. 
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Supplemental Figure VI. Control experiments to validate infection of hMA in organ 
culture with adenoviral vectors expressing GFP (control) or Kv1.5-GFP. A. 
Microphotographs showing direct visualization of GFP-labelled cells form arterial rings 
in organ culture (upper image) or with confocal image of a paraffin section of hMA 
(lower image), nuclei labelled with Hoechst (blue) and scale bar = 50 µm. B. qPCR 
determination of the relative amount of GFP in hMA rings infected with AAV-GFP (kept 
in 0% or 20% FBS for two weeks) or with AAV-Kv1.5-GFP (kept in 20%FBS for two 
weeks). GFP mRNA was used as a control of infection, being absent from uninfected 
vessels. Data are Mean ± SEM of 4- 5 independent experiments. *p<0.05 compared to 
0%FBS. C. Immunohistochemical labelling for GFP in paraffin-embedded cross-sections 
from hMA infected with AAV-GFP (left panel) or AAV-Kv1.5 (middle panel) and kept in 
organ culture with 20% FBS. Right panel show a negative control. 20X objective, scale 
bar = 100 µm.  
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Supplemental Figure VII. Characterization of the proliferation rate in AAV-Kv1.5- 
infected hMA rings in organ culture. Proliferation rate was estimated by counting the 
nuclei present in the intima and media layer of hMA sections stained with Hoechst, as 
described in figure 2A. The experimental groups included control (AAV-GFP-infected 
samples, 0%FBS) and AAV-GFP-infected or AAV-Kv1.5-infected samples incubated with 
20% FBS alone or in combination with PAP-1 (100nM) as indicated. Each bar is the 
mean ± SEM of 3-6 experiments. **p<0.01, ***p<0.001 compared to 20%FBS-GFP. 
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Supplemental Figure VIII. Immunohistochemical characterization of the GFP and 
ccMYOCD-infected vessels in organ culture. Representative microphotographs 
showing the labelling of the smooth muscle contractile proteins Myosin heavy chain II 
(MHCII, upper panels) and SM22 (lower panels) in paraffin-embedded cross-sections of 
hMA infected with Lv-GFP or the myocardin knock-down Lv-ccMYOCD. Arterial rings 
were kept in organ culture for 14 days in 0% or 20%FBS as indicated. MHCII and SM22 
labelling can be clearly detected only in GFP infected cell kept in 0%FBS (left panels) 
and decreased significantly in the cc-MYOCD-0%FBS and GFP-20%FBS conditions.  
Right panels show the negative control for each antibody in a GFP-0% FBS sample. 10x 
objective (NA=0.3), scale bar 100µm. L = lumen side. 
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Supplemental Figure IX. mRNA expression levels of Kv1.5 and Myocardin with the 
different myocardin knock-down vectors.  Myocardin knock-down experiments were 
carried out transducing hMA tissues with three different CRISPR/Cas9 vectors against 
Myocardin expression: CRISPR-1 (targeting exon 1), CRISPR-10 (targeting Exon 10), 
ccMYOCD (targeting both exons). Lv-GFP was used as control. Bar plot shows relative 
expression of MYOCD (white bars) and Kv1.5 (grey bars) using Lv-GFP as calibrator.  
The effects of ccMYOCD were reproduced with the CRISPR-1 while CRISPR-10 has no 
effect on myocardin and Kv1.5 mRNA expression.  
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Supplemental Table I. CRISPOR scores for gRNAs targeting myocardin Exon1 and 
Exon10. Table shows the CRISPOR scores obtained for gRNAs targeting myocardin used 
(http://crispor.org). Row 2 indicates two specificity scores: MIT (uses the formula from 
Crispr Website) and CDF (Cutting frequency determination, from guidescan.com) to 
predict how much an RNA guide sequence for a target may produce off-target 
cleavage. The scores range from 0-100, values over 50 are recommended. For the 
selected gRNAs both scores are higher than 50. The efficiency score (row 3), predicts 
how a target may be cut by its RNA guide sequence, it ranges from 0 to 100, and our 
efficiencies are higher than 50 for both gRNAs. Rows 4 and 5 show the number of 
possible off-targets in the genome for each number of mismatches (from 0 to 4 
mismatches) and which are the most likely off-targets. There is one off-target with four 
mismatches for gRNA myocardin exon1 and also one with two mismatches for gRNA 
myocardin exon 10. 
  
CRISPOR 
Scores 
gRNA spacer myocardin Exon1 
5’-GAACTTGCTCCTAATCAGCA-3’ 
gRNA spacer myocardin Exon 10 
5’-GTGGTAGAAGCCGTTGGACA-3’ 
Specificity 
score 
MIT- 79 
CFD- 86 
MIT- 88 
CFD- 93 
Efficiency 
score 64 64 
Off-target 
mismatch 
counts 
0-0-1-11-123 0-0-1-8-75 
Most likely 
off-target 0-0-0-0-1 0-0-1-0-0 
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Major Resources Tables 
Antibodies 
Target antigen Vendor or Source Catalog # Working concentration 
Lot # (preferred 
but not required) 
Kv1.5 Alomone APC004 12 µg/ml   
GFP NeuroMab 75-131 20 µg/ml   
Myocardin Sigma  SAB4200539 20 µg/ml   
Myosin Heavy Chain II  Abcam AB683 20 µg/ml  
SM22 Abcam AB14106 8 µg/ml   
αSMA  Abcam AB7817 4 µg/ml  
Target sequences (sgRNA) for myocardin knockdown 
Myocardin exon  sequence 
Exon 1 MYOCD EX1 FW: 5’-CACCGAACTTGCTCCTAATCAGCA -3’ 
MYOCD EX1 RE: 5’-AAACTGCTGATTAGGAGCAAGTTC-3’. 
Exon 10 MYOCD EX10 FW: 5’-CACCGTGGTAGAAGCCGTTGGACA-3’ 
MYOCD EX10 RE 5’-AAACTGTCCAACGGCTTCTACCAC-3’. 
Taqman Assays 
gene  Protein  Assay ID (Thermo-Fisher) 
KCNA3 Kv1.3 Hs00704943_s1 
KCNA5 Kv1.5 Hs00266898_S1 
CNN1 Calponin Hs00154543_m1 
MYOCD Myocardin Hs00538076_m1 
KCNAB2  Kvβ2 Hs01547935_m1 
COL1A1  Collagen I Hs00164004_m1 
COL3A1  Collagen III Hs00943809_m1 
COL8A1  Collagen VIII Hs00156669_m1 
HsRPL18 Ribosomal protein L18 F: 5’-aactgatgatgtgcgggttc-3’, R: 5’-cagctggtcgaaagtgagg-3’  
Probe: 5’-FAM-ctgaaggtatgtgcactgcgcgtga-BHQ2-3’ 
KCNA1 Kv1.1 Hs00264798_s1 
KCNA2 Kv1.2 Hs00270656_s1 
KCNA4 Kv1.4 Hs00937357_s1 
KCNA6 Kv1.6 Hs00266903_s1 
Cultured Cells (primary VSMCs from human mammary arteries) 
Name Vendor or Source* Sex (F, M) 
0013/384/02/0/01 COLMAH collection (HERACLES network) M 
0013/404/02/0/01 COLMAH collection (HERACLES network) M 
0013/407/02/0/01 COLMAH collection (HERACLES network) F 
0013/412/02/0/01 COLMAH collection (HERACLES network) M 
0013/386/02/0/01 COLMAH collection (HERACLES network) M 
0013/389/02/0/01 COLMAH collection (HERACLES network) M 
0013/368/02/0/01 COLMAH collection (HERACLES network) F 
0013/408/02/0/01 COLMAH collection (HERACLES network) M 
*(http:// www.redheracles.net/plataformas/en_coleccion-muestrasarteriales-humanas.html) 
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Other Cultured Cells  
Name Vendor or Source* Sex (F, M) 
hCASMCs Gibco (Life Technologies,  cat # 1130140) Unknown 
 
 
